Novo Nordisk expects Wegovy limits to last "some months"
![Lars Fruergaard Jørgensen, CEO of Novo Nordisk | Photo: Mads Claus Rasmussen/Ritzau Scanpix](https://photos.watchmedier.dk/watchmedier/resize:fill:3840:0:0/plain/https://photos.watchmedier.dk/Images/15746365/bsy2el/ALTERNATES/schema-16_9/20230421-153518-L-8640x5760ma.jpg)
The great demand for Novo Nordisk’s newest obesity drug, Wegovy (semaglutide), looks to continue, and the Danish drugmaker has therefore once again resorted to limiting access to the drug, explains Novo Nordisk CEO Lars Fruergaard Jørgensen.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
Get full access for you and your coworkers
Start a free company trial todayRelated articles
High demand makes Novo Nordisk hit the brakes on Wegovy
For subscribers